

Silvio Bellino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5532949/publications.pdf>

Version: 2024-02-01

66
papers

1,714
citations

304743

22
h-index

302126

39
g-index

69
all docs

69
docs citations

69
times ranked

1943
citing authors

#	ARTICLE	IF	CITATIONS
1	Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. <i>Journal of Clinical Medicine</i> , 2016, 5, 67.	2.4	123
2	Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. <i>Psychiatry Research</i> , 2000, 96, 91-98.	3.3	110
3	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	10.4	96
4	Dysmorphic concern symptoms and personality disorders: A clinical investigation in patients seeking cosmetic surgery. <i>Psychiatry Research</i> , 2006, 144, 73-78.	3.3	80
5	Clinical picture of obsessive-compulsive disorder with poor insight: A regression model. <i>Psychiatry Research</i> , 2005, 136, 223-231.	3.3	75
6	Depressive and negative symptoms in schizophrenia: different effects on clinical features. <i>Comprehensive Psychiatry</i> , 2005, 46, 304-310.	3.1	65
7	Combined Treatment of Major Depression in Patients with Borderline Personality Disorder: A Comparison with Pharmacotherapy. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 453-460.	1.9	63
8	Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2019, 10, 67.	2.6	60
9	Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors. <i>CNS Drugs</i> , 2002, 16, 273-283.	5.9	59
10	Efficacy and Tolerability of Quetiapine in the Treatment of Borderline Personality Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1042-1046.	2.2	50
11	Adaptation of Interpersonal Psychotherapy to Borderline Personality Disorder: A Comparison of Combined Therapy and Single Pharmacotherapy. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 74-81.	1.9	45
12	Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid. <i>Journal of Psychopharmacology</i> , 2014, 28, 125-132.	4.0	45
13	Relationships of Age at Onset With Clinical Features and Cognitive Functions in a Sample of Schizophrenia Patients. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 908-914.	2.2	44
14	Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder. <i>CNS Drugs</i> , 2008, 22, 671-692.	5.9	42
15	Oxcarbazepine in the Treatment of Borderline Personality Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1111-1115.	2.2	41
16	Major Depression in Patients with Borderline Personality Disorder: A Clinical Investigation. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 234-238.	1.9	37
17	Quality of Life of Patients Who Undergo Breast Reconstruction after Mastectomy: Effects of Personality Characteristics. <i>Plastic and Reconstructive Surgery</i> , 2011, 127, 10-17.	1.4	37
18	Early Detection and Outcome in Borderline Personality Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 710.	2.6	37

#	ARTICLE	IF	CITATIONS
19	Combined Therapy of Major Depression with Concomitant Borderline Personality Disorder: Comparison of Interpersonal and Cognitive Psychotherapy. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 718-725.	1.9	34
20	Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5257.	4.1	33
21	Pharmacotherapy of Borderline Personality Disorder: A Systematic Review. <i>Current Medicinal Chemistry</i> , 2011, 18, 3322-3329.	2.4	25
22	Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. <i>Journal of Psychopharmacology</i> , 2010, 24, 333-339.	4.0	24
23	Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 47-61.	1.8	24
24	Borderline Personality Disorder: Risk Factors and Early Detection. <i>Diagnostics</i> , 2021, 11, 2142.	2.6	23
25	Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up. <i>Psychiatry Research</i> , 2016, 240, 151-156.	3.3	21
26	Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2767-2779.	2.2	21
27	The Role of Trauma in Early Onset Borderline Personality Disorder: A Biopsychosocial Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 721361.	2.6	21
28	No Effect of Serotonergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. <i>Psychiatry Investigation</i> , 2013, 10, 180.	1.6	20
29	Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 567-577.	3.8	19
30	Unblending Borderline Personality and Bipolar Disorders. <i>Journal of Psychiatric Research</i> , 2017, 91, 90-97.	3.1	19
31	Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial. <i>CNS Drugs</i> , 2017, 31, 809-819.	5.9	19
32	Autobiographical memories, identity disturbance and brain functioning in patients with borderline personality disorder: An fMRI study. <i>Heliyon</i> , 2019, 5, e01323.	3.2	19
33	The Impact of SARS-CoV-2 Infection on Youth Mental Health: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 772.	3.2	19
34	Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. <i>Clinical Drug Investigation</i> , 2018, 38, 367-372.	2.2	18
35	Accuracy of self-assessment of real-life functioning in schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 11.	3.6	18
36	Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: Predictors of response. <i>Psychiatry Research</i> , 2015, 226, 284-288.	3.3	16

#	ARTICLE	IF	CITATIONS
37	Long Term Treatment of Obsessive-Compulsive Disorder. <i>CNS Drugs</i> , 1998, 10, 247-255.	5.9	15
38	Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. <i>Psychiatry Research</i> , 2008, 161, 206-212.	3.3	15
39	Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2020, 11, 223.	2.6	15
40	Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability. <i>Depression Research and Treatment</i> , 2011, 2011, 1-7.	1.3	12
41	Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6042.	4.1	12
42	Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. <i>Clinical Drug Investigation</i> , 2019, 39, 169-178.	2.2	11
43	Trauma and psychopathology associated with early onset BPD: an empirical contribution. <i>Journal of Psychiatric Research</i> , 2020, 131, 54-59.	3.1	11
44	Mental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids. <i>Biomedicines</i> , 2021, 9, 850.	3.2	11
45	Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. <i>Psychiatry Research</i> , 1995, 57, 49-56.	3.3	9
46	An open-label, randomized, prospective comparison of sertraline and amisulpride in the treatment of dysthymia in the elderly. <i>Current Therapeutic Research</i> , 1997, 58, 798-808.	1.2	9
47	Recognition and Treatment of Dysthymia in Elderly Patients. <i>Drugs and Aging</i> , 2000, 16, 107-121.	2.7	9
48	Treating Depression: What Patients Want; Findings From a Randomized Controlled Trial in Primary Care. <i>Psychosomatics</i> , 2016, 57, 616-623.	2.5	9
49	Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset. <i>Diagnostics</i> , 2021, 11, 2146.	2.6	8
50	Clinical features of dysthymia and age: a clinical investigation. <i>Psychiatry Research</i> , 2001, 103, 219-228.	3.3	7
51	Recent approaches to pharmacotherapy of personality disorders. <i>Neuropsychiatry</i> , 2011, 1, 259-273.	0.4	6
52	Interpersonal Psychotherapy Adapted for Borderline Personality Disorder (IPT-BPD): A Review of Available Data and a Proposal of Revision. , 2015, 05, .		5
53	The Italian Version of the Borderline Personality Disorder Severity Index IV: Psychometric Properties, Clinical Usefulness, and Possible Diagnostic Implications. <i>Journal of Personality Disorders</i> , 2018, 32, 207-219.	1.4	5
54	Effectiveness of psychosocial treatments on symptoms and functional domains in schizophrenia spectrum disorders: a prospective study in a real-world setting. <i>Disability and Rehabilitation</i> , 2019, 41, 2799-2806.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 620.	4.1	5
56	How Interpersonal Psychotherapy Changes the Brain. <i>Journal of Clinical Psychiatry</i> , 2021, 83, .	2.2	5
57	Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders. <i>Current Psychopharmacology</i> , 2012, 2, 5-17.	0.3	4
58	Pharmacotherapy of personality disorders: what we know and what we have to search for. <i>Future Neurology</i> , 2017, 12, 199-222.	0.5	4
59	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 46-54.	2.6	4
60	Interpersonal Psychotherapy as a Single Treatment for Borderline Personality Disorder: A Pilot Randomized-Controlled Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 578910.	2.6	3
61	Pharmacological Treatment for Social Cognition: Current Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7457.	4.1	3
62	New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder. <i>Current Psychopharmacology</i> , 2012, 1, 86-96.	0.3	1
63	Treatment-induced brain plasticity in borderline personality disorder: review of functional MRI studies. <i>Future Neurology</i> , 2018, 13, 225-238.	0.5	1
64	Editorial: Psychosis and Personality Disorders: Do We Need Early Diagnosis for Successful Treatment?. <i>Frontiers in Psychiatry</i> , 2020, 11, 584.	2.6	0
65	Editorial: Borderline Personality Disorders in Adolescents: Clinical Challenges and Recent Advances. <i>Frontiers in Psychiatry</i> , 2022, 13, 854833.	2.6	0
66	The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 18.	3.6	0